SEC filing · 8-K

Valion Bio, Inc.: Executive or director change

Valion Bio appointed board member Dean Zikria as Interim Chief Executive Officer and announced board leadership changes.

Filed September 23, 2026

Neutral news

What happened

On September 22, 2026, Valion Bio appointed board member Dean Zikria as Interim Chief Executive Officer under a consulting agreement terminating January 22, 2027.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Valion Bio, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.